Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ibudilast: Phase IIa data

In a 2-week, double-blind, placebo-controlled, dose-escalation, Australian Phase IIa trial in 50 patients

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE